Phase 3 trial reports one dose of Ad5-nCoV COVID-19 vaccine is safe and effective, including against severe disease
Researcher shows novel drug significantly improves signs and symptoms of generalized pustular psoriasis
23 December 2021Omicron is latest blow to pandemic-weary front-line workers
24 December 2021Phase 3 trial reports one dose of Ad5-nCoV COVID-19 vaccine is safe and effective, including against severe disease
One dose of Ad5-nCoV (Convidecia), a COVID-19 vaccine developed in China, is 57.5% effective against symptomatic COVID-19 and 91.7% effective against severe COVID-19 disease beginning 28 days postvaccination, according to a phase 3 randomised controlled trial published in The Lancet.
